A phase II study of the pineal hormones melatonin and 5-methoxytryptamine plus cannabidiol in association with angiotensin 1-7 in the treatment of advanced solid tumour patients eligible for the only best supportive care

Abstract: The recent advances in the investigation of tumour biology have demonstrated that the human body may produce several molecules provided by a natural anticancer activity without any toxicity, in particular the pineal hormones melatonin (MLT), 5-methoxytryptamine (5-MTT) and pinealine, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lissoni, Paolo, Porro, Giorgio, Messina, Giusy, Galli, Carla, Di Fede, Giuseppe, Valentini, Agnese, Simoes-e-Silva, Ana Cristina, Cardinali, Daniel Pedro
Formato: Artículo
Lenguaje:Inglés
Publicado: Lupin 2022
Materias:
ANGIOTENSINA 1-7
CANNABINOIDES
MELATONINA
CANCER
METASTASIS
CUIDADOS PALIATIVOS
Acceso en línea:https://repositorio.uca.edu.ar/handle/123456789/13686
Aporte de:
Repositorio Institucional de la Universidad Católica Argentina (UCA) de Universidad Católica Argentina
id I33-R139123456789-13686
record_format dspace
institution Universidad Católica Argentina
institution_str I-33
repository_str R-139
collection Repositorio Institucional de la Universidad Católica Argentina (UCA)
language Inglés
topic ANGIOTENSINA 1-7
CANNABINOIDES
MELATONINA
CANCER
METASTASIS
CUIDADOS PALIATIVOS
spellingShingle ANGIOTENSINA 1-7
CANNABINOIDES
MELATONINA
CANCER
METASTASIS
CUIDADOS PALIATIVOS
Lissoni, Paolo
Porro, Giorgio
Messina, Giusy
Galli, Carla
Di Fede, Giuseppe
Valentini, Agnese
Simoes-e-Silva, Ana Cristina
Cardinali, Daniel Pedro
A phase II study of the pineal hormones melatonin and 5-methoxytryptamine plus cannabidiol in association with angiotensin 1-7 in the treatment of advanced solid tumour patients eligible for the only best supportive care
topic_facet ANGIOTENSINA 1-7
CANNABINOIDES
MELATONINA
CANCER
METASTASIS
CUIDADOS PALIATIVOS
description Abstract: The recent advances in the investigation of tumour biology have demonstrated that the human body may produce several molecules provided by a natural anticancer activity without any toxicity, in particular the pineal hormones melatonin (MLT), 5-methoxytryptamine (5-MTT) and pinealine, the endogenous cannabinoids, oxytocin, and angiotensin 1-7 (Ang 1-7). Unfortunately, despite their well confirmed anticancer and non-toxic properties, very few clinical studies have been performed in an attempt to evaluate the potential therapeutic efficacy of the endogenous human anticancer molecules in the treatment of cancer patients, at least of those eligible for the only palliative therapy. Moreover, most studies have been generally limited to the use of the only pineal MLT. The present preliminary study was carried out to evaluate the anticancer efficacy of an oral administration of MLT (100 mg in the dark period) in association with 5-MTT (10 mg in the light period), the cannabinoid agent cannabidiol (CBD) ( 10 mg twice/day) and Ang 1-7 (0.5 mg/twice day) in a group of 14 untreatable advanced or metastatic cancer patients. The clinical response consisted of partial response (PR) in 2/14 (14%), and stable disease (SD) in 8/14 (57%). Then, a disease control (PR + SD) was achieved in 10/14 (71%), whereas the remaining 4/14 (29%) had a progressive disease. Moreover, disease control was associated with a significant increase in lymphocyte-to-monocyte ratio (LMR), by showing that the control of the neoplastic growth is mediated at least in part by an improvement in the antitumor immune status of cancer patients.The treatment was well tolerated in all patients, and in particular no important decline in blood pressure values occurred. On the contrary, a clear improvement in asthenia was obtained in 8/10 (80%) patients with important asthenia prior to study. This preliminary study may suggest that after the failure of the common standard anticancer therapies, the administration of the main endogenous anticancer neuroendocrine molecules, firstly MLT and Ang 1-7, could constitute an alternative approach to cancer patients instead of the simple best supportive care alone.
format Artículo
author Lissoni, Paolo
Porro, Giorgio
Messina, Giusy
Galli, Carla
Di Fede, Giuseppe
Valentini, Agnese
Simoes-e-Silva, Ana Cristina
Cardinali, Daniel Pedro
author_facet Lissoni, Paolo
Porro, Giorgio
Messina, Giusy
Galli, Carla
Di Fede, Giuseppe
Valentini, Agnese
Simoes-e-Silva, Ana Cristina
Cardinali, Daniel Pedro
author_sort Lissoni, Paolo
title A phase II study of the pineal hormones melatonin and 5-methoxytryptamine plus cannabidiol in association with angiotensin 1-7 in the treatment of advanced solid tumour patients eligible for the only best supportive care
title_short A phase II study of the pineal hormones melatonin and 5-methoxytryptamine plus cannabidiol in association with angiotensin 1-7 in the treatment of advanced solid tumour patients eligible for the only best supportive care
title_full A phase II study of the pineal hormones melatonin and 5-methoxytryptamine plus cannabidiol in association with angiotensin 1-7 in the treatment of advanced solid tumour patients eligible for the only best supportive care
title_fullStr A phase II study of the pineal hormones melatonin and 5-methoxytryptamine plus cannabidiol in association with angiotensin 1-7 in the treatment of advanced solid tumour patients eligible for the only best supportive care
title_full_unstemmed A phase II study of the pineal hormones melatonin and 5-methoxytryptamine plus cannabidiol in association with angiotensin 1-7 in the treatment of advanced solid tumour patients eligible for the only best supportive care
title_sort phase ii study of the pineal hormones melatonin and 5-methoxytryptamine plus cannabidiol in association with angiotensin 1-7 in the treatment of advanced solid tumour patients eligible for the only best supportive care
publisher Lupin
publishDate 2022
url https://repositorio.uca.edu.ar/handle/123456789/13686
work_keys_str_mv AT lissonipaolo aphaseiistudyofthepinealhormonesmelatoninand5methoxytryptaminepluscannabidiolinassociationwithangiotensin17inthetreatmentofadvancedsolidtumourpatientseligiblefortheonlybestsupportivecare
AT porrogiorgio aphaseiistudyofthepinealhormonesmelatoninand5methoxytryptaminepluscannabidiolinassociationwithangiotensin17inthetreatmentofadvancedsolidtumourpatientseligiblefortheonlybestsupportivecare
AT messinagiusy aphaseiistudyofthepinealhormonesmelatoninand5methoxytryptaminepluscannabidiolinassociationwithangiotensin17inthetreatmentofadvancedsolidtumourpatientseligiblefortheonlybestsupportivecare
AT gallicarla aphaseiistudyofthepinealhormonesmelatoninand5methoxytryptaminepluscannabidiolinassociationwithangiotensin17inthetreatmentofadvancedsolidtumourpatientseligiblefortheonlybestsupportivecare
AT difedegiuseppe aphaseiistudyofthepinealhormonesmelatoninand5methoxytryptaminepluscannabidiolinassociationwithangiotensin17inthetreatmentofadvancedsolidtumourpatientseligiblefortheonlybestsupportivecare
AT valentiniagnese aphaseiistudyofthepinealhormonesmelatoninand5methoxytryptaminepluscannabidiolinassociationwithangiotensin17inthetreatmentofadvancedsolidtumourpatientseligiblefortheonlybestsupportivecare
AT simoesesilvaanacristina aphaseiistudyofthepinealhormonesmelatoninand5methoxytryptaminepluscannabidiolinassociationwithangiotensin17inthetreatmentofadvancedsolidtumourpatientseligiblefortheonlybestsupportivecare
AT cardinalidanielpedro aphaseiistudyofthepinealhormonesmelatoninand5methoxytryptaminepluscannabidiolinassociationwithangiotensin17inthetreatmentofadvancedsolidtumourpatientseligiblefortheonlybestsupportivecare
AT lissonipaolo phaseiistudyofthepinealhormonesmelatoninand5methoxytryptaminepluscannabidiolinassociationwithangiotensin17inthetreatmentofadvancedsolidtumourpatientseligiblefortheonlybestsupportivecare
AT porrogiorgio phaseiistudyofthepinealhormonesmelatoninand5methoxytryptaminepluscannabidiolinassociationwithangiotensin17inthetreatmentofadvancedsolidtumourpatientseligiblefortheonlybestsupportivecare
AT messinagiusy phaseiistudyofthepinealhormonesmelatoninand5methoxytryptaminepluscannabidiolinassociationwithangiotensin17inthetreatmentofadvancedsolidtumourpatientseligiblefortheonlybestsupportivecare
AT gallicarla phaseiistudyofthepinealhormonesmelatoninand5methoxytryptaminepluscannabidiolinassociationwithangiotensin17inthetreatmentofadvancedsolidtumourpatientseligiblefortheonlybestsupportivecare
AT difedegiuseppe phaseiistudyofthepinealhormonesmelatoninand5methoxytryptaminepluscannabidiolinassociationwithangiotensin17inthetreatmentofadvancedsolidtumourpatientseligiblefortheonlybestsupportivecare
AT valentiniagnese phaseiistudyofthepinealhormonesmelatoninand5methoxytryptaminepluscannabidiolinassociationwithangiotensin17inthetreatmentofadvancedsolidtumourpatientseligiblefortheonlybestsupportivecare
AT simoesesilvaanacristina phaseiistudyofthepinealhormonesmelatoninand5methoxytryptaminepluscannabidiolinassociationwithangiotensin17inthetreatmentofadvancedsolidtumourpatientseligiblefortheonlybestsupportivecare
AT cardinalidanielpedro phaseiistudyofthepinealhormonesmelatoninand5methoxytryptaminepluscannabidiolinassociationwithangiotensin17inthetreatmentofadvancedsolidtumourpatientseligiblefortheonlybestsupportivecare
bdutipo_str Repositorios
_version_ 1764820526406041601

Ejemplares similares